Deutsche Bank analyst George Hill lowered the firm’s price target on Humana to $562 from $575 and keeps a Buy rating on the shares post the Q4 results. Humana recently announced that it will be exiting the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Fed Employee health benefit plans and associated rewards programs, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HUM:
- Evolent Health price target raised to $45 from $40 at BTIG
- Humana to exit Employer Group Commercial Medical Products business
- Humana raises quarterly dividend 12.4% to 88.5c from 78.75c per share
- Humana and ChenMed announce five-year network agreement
- Humana price target lowered to $560 from $580 at Truist
